Open AccessAntiemetic prophylaxis with temozolomide: an audit from a tertiary care center
Author(s) -
Vijay Patil,
Arun Chandrasekharan,
Dilip Harindran Vallathol,
Mridul Malhotra,
Ram Abhinav,
Priti Agarwal,
Anu Rajpurohit,
Raees Tonse,
Atanu Bhattacharjee,
Rakesh Jalali
Publication year - 2019
Publication title -
neuro-oncology practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.666
H-Index - 14
eISSN - 2054-2585
pISSN - 2054-2577
DOI - 10.1093/nop/npz009
Subject(s) - ondansetron , nausea , medicine , antiemetic , olanzapine , vomiting , anesthesia , domperidone , schizophrenia (object oriented programming) , psychiatry , dopamine
In our previous experience, a significant proportion of patients who received 5-HT 3 antagonist monotherapy with adjuvant temozolomide (150-200 mg/m 2 ) had chemotherapy-induced nausea and vomiting (CINV). This is an audit comparing the multiple antiemetic therapies in the prevention of temozolomide-associated CINV.